Our Pipeline
Deargen streamlines the initial R&D stage of new drug development with A.I. Each of Deargen's programs focuses on diseases with high medical demands, such as anticancer drugs, cardiovascular and metabolic diseases, neurological diseases, and immune diseases.
Oncology
Neurology
Rare Disease
Dermatology
Crop Protectant
4D Program
The 4D (Deargen-Driven Drug Development) program is a new drug development pipeline led by Deargen from the discovery of Hit substances. Using A.I, we develop optimal new drug candidates through the iterative process of prediction, synthesis, validation, and re-learning.
DGD-201 | DLBCL
DGP-101 | Immuno-oncology
DGP-108 | NSCLC
DGP-113 | TNBC
DGP-114 | Ovarian Cancer
Co-Developed Program
Deargen is developing new drugs through various cooperation with domestic and overseas drug developers.
DGC610 | Rare Disease
DGC803 | Herbicide
DGC804 | Fungicide
DGC805 | Herbicide
DGC601 | Neurology
DGC810 | Dermatology
Service Agreement
DGC811 | Dermatology
Service Agreement